X

Stay Connected

Sign Up for Updates

network1.png

PPA strives to improve patient health, advance medical innovation and fuel economic growth.

LEARN MORE
network1.png

The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.

LEARN MORE
network1.png

Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines.

LEARN MORE
network1.png

We Work For Health aims to increase awareness by uniting workers throughout the industry.

LEARN MORE
network1.png

Patent protection should always be considered by an inventor during the initial stages of their invention.

LEARN MORE
logo_white_MyOldMeds-New-1.png

Working to spread awareness and education about the importance of secure drug disposal.

LEARN MORE
LTAC_NEW21.png

Many Americans are struggling to afford their medicines and have important questions about their medicine costs. Let's Talk About Cost addresses these questions.

LEARN MORE
logo_white_LTAM.png

There are a lot of conversations in Washington about how to change Medicare Part D, but they aren't always focused on what seniors care about most: affordability and predictability.

LEARN MORE
 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Nonprofit hospitals fall short on community benefit, studies show

By Gabby Migliara  |    April 24, 2023
Nonprofit hospitals are supposed to help provide access to crucial treatment and services in our most vulnerable communities. But recent research adds to the mountain of evidence showing nonprofit...   Read More

Why Congress should prioritize fixing the 340B program

By Nicole Longo  |    March 2, 2023
Nearly all Americans nationwide agree: Lowering out-of-pocket costs for health care should be a top priority for policymakers. Luckily, there are commonsense policies Congress could implement to...   Read More

What they are saying: Nonprofit hospitals are gaming the system at the expense of patients

By Gabby Migliara  |    February 21, 2023
There have been some alarming stories uncovered by the media on ways nonprofit hospitals — many of which participate in the 340B drug pricing program — are taking advantage of the system and their...   Read More

ICYMI: PhRMA kicks off the year at the 2023 J.P. Morgan Health Care Conference

By Katie Koziara  |    January 19, 2023
This January, PhRMA joined health care leaders, investors, R&D experts and members of the media at the 2023 J.P. Morgan Health Care Conference in San Francisco, CA. During this week, we discussed...   Read More

340B program continues to drive shift in care to more expensive hospital settings

By Nicole Longo  |    December 15, 2022
Yet another study highlights the unintended consequences of the 340B program, which is increasing costs for patients and the health care system as a whole. In this case, the Berkeley Research Group...   Read More

The 340B program is interfering with the U.S. biosimilars market and impacting patient costs

By Nicole Longo  |    November 21, 2022
Research has shown that 340B hospitals are more likely to prescribe more expensive medicines and significantly mark up the price of medicines. For example, 340B hospitals received nearly five times...   Read More

Three ways 340B is failing vulnerable patients

By Nicole Longo  |    October 20, 2022
The 340B Drug Pricing Program is 30 years old this year, but as The New York Times recently spelled out, the program has become a profit engine for large health systems over the years instead of a...   Read More

If patients aren’t benefiting from the 340B program, who is?

By Nicole Longo  |    October 6, 2022
The 340B Drug Pricing Program was designed to help vulnerable patients improve access to their medicines through manufacturer discounts to specific safety-net, non-profit hospitals and federally...   Read More

New data: The 340B program is driving up costs for patients and our health care system

By Nicole Longo  |    September 15, 2022
Guess what? The 340B program grew, yet again, hitting a whopping $43.9 billion in sales at the discounted 340B price in 2021. But there has not been evidence of corresponding growth in care provided...   Read More

Word of the Month: 340B covered entity

By Nicole Longo  |    August 29, 2022
What is a 340B covered entity?   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates

Trending Posts

Most Popular Posts

Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004

Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."